Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2021-08-19 00:00:00 ET · period of report 2021-08-17 · accession 0001567619-21-016145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-08-19 | 2021-08-17 | ATRA | Dupont Jakob | EVP, Head of R, D | S - Sale | $12.53 | -2,152 | 92.8K | -2% | -$27.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-17 | S | D | 2,152 | $12.53 | 92,793 | D | — | — | (F2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. |